Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans

Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans Susanne Lerche 1 , Birgitte Brock 1 , Jørgen Rungby 1 , Hans E. Bøtker 2 , Niels Møller 3 , Anders Rodell 4 , Bo Martin Bibby 5 , Jens J. Holst 6 , Ole Schmitz 1 and Albert Gjedde 4 1 Institute of Pharmacology, University of Aar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2008-02, Vol.57 (2), p.325-331
Hauptverfasser: LERCHE, Susanne, BROCK, Birgitte, RUNGBY, Jørgen, BØTKER, Hans E, MØLLER, Niels, RODELL, Anders, BIBBY, Bo Martin, HOLST, Jens J, SCHMITZ, Ole, GJEDDE, Albert
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans Susanne Lerche 1 , Birgitte Brock 1 , Jørgen Rungby 1 , Hans E. Bøtker 2 , Niels Møller 3 , Anders Rodell 4 , Bo Martin Bibby 5 , Jens J. Holst 6 , Ole Schmitz 1 and Albert Gjedde 4 1 Institute of Pharmacology, University of Aarhus, Aarhus, Denmark 2 Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark 3 Department of Endocrinology M, Aarhus University Hospital, Aarhus, Denmark 4 PET-Center, Aarhus University Hospital, Aarhus, Denmark 5 Department of Biostatistics, University of Aarhus, Aarhus, Denmark 6 Department of Medical Physiology, University of Copenhagen, Panum Institute, Copenhagen, Denmark Address correspondence and reprint requests to Susanne Lerche, MD, Institute of Pharmacology, University of Aarhus, The Bartholin Building, University Park 1240, 8000 Aarhus C, Denmark. E-mail: lerche{at}ki.au.dk Abstract OBJECTIVE— Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents suggests a protective effect of GLP-1 on brain tissue. The mechanism is unknown. We therefore tested whether these neuroprotective effects could relate to changes of glucose transport and consumption. RESEARCH DESIGN AND METHODS— We studied 10 healthy men in a randomized, double-blinded, placebo-controlled cross-over experiment. We used positron emission tomography to determine the acute insulin-independent effect of GLP-1 on unidirectional glucose transport into the brain during a pituitary-pancreatic normoglycemic (plasma glucose ∼4.5 mmol/l) clamp with 18-fluoro-deoxy-glucose as tracer. RESULTS— On average, GLP-1 reduced cerebral glucose transport by 27% in total cerebral gray matter ( P = 0.05) and by 25–30% in individual gray matter regions ( P = 0.02–0.06). The same regions revealed a uniform trend toward similarly reduced cerebral glucose metabolism. Consequently, the intracerebral glucose concentration remained constant in all regions, with and without GLP-1. CONCLUSIONS— We have demonstrated that a hormone involved in postprandial glucose regulation also limits glucose delivery to brain tissue and hence provides a possible regulatory mechanism for the link between plasma glucose and brain glucose. Because GLP-1 reduces glucose uptake across the intact blood-brain barrier at normal glycemia, GLP-1 may also protect the brain by limiting intracerebral glucose fl
ISSN:0012-1797
1939-327X
DOI:10.2337/db07-1162